Trial Profile
The use of intravenous Iron oxide as a contrast agent for cardiac magnetic resonance imaging.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 23 Aug 2015
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Cardiovascular disorders
- Focus Diagnostic use
- 23 Aug 2015 New trial record